Is there any update or insights on their initiative of evluating their current business by Grant Thornton ?
Posts tagged Value Pickr
Chirag’s Portfolio (10-02-2024)
I would also look at Rategain technologies in technology space.its kind of a monopolistic business they have built.Bullish on the travel segment aswell
Kreon Financial Services aka StuCred……The Rising Micro Cap (10-02-2024)
Results don’t look too good. Company finally wrote off 4.78Cr as bad debt, the biggest part in their expenses leading to a loss making quarter.
Disc. Holding a tracking postion.
Godawari Power – Any Trackers? (10-02-2024)
GPIL has 0 royalties to be paid on Iron ore mines. As it is in the old mining regime. Likes of Jsl and JSPL have to pay through the nose at these auctions, and continue royalties which are at 100% Premium. Which gives a natural advantage in being a low cost producer.
Ebitda per tonne will likely be close to 10,000 rs and at peak this capex can add 1800 crores of Ebitda assuming 90% Utilisation of the steel plant.
Disclaimer: No recommendation to buy or sell.
Godawari Power – Any Trackers? (10-02-2024)
How much realisations and ROCE they are expecting from this integrated steel plant?
Chirag’s Portfolio (10-02-2024)
Mostly I agree about what you said… But do you really think Polyplex is a junk insvestment? Its true that polyplex, cosmo first … stocks like these are going to suffer for some more time, but that should not make it a junk, especially, if someone is thinking about its long term prospect.
Please let me know what do you think. Thanks,
Natural Capsules – Pharma play with solid fundamentals (10-02-2024)
Not according to their recent investor presentation, but they do state a meeting is scheduled soon and they are hoping for a favorable resolution.
Natural Capsules – Pharma play with solid fundamentals (10-02-2024)
Short Notes on Q3FY24 Results.
- Very poor showing across the board, significant margin compression due to increased freight costs.
- Revenue at 40 Cr, 12% de-growth YoY, EBITDA at 4.72 Cr, 52% degrowth YoY.
- EBITDA margins at 11.81%, down from 21% last year.
- PAT and EPS down ~77% YoY.
- Despite the headwinds in Q3, management expects the business to improve in coming quarters.
Capsules Segment
- Struggled with exports market, a significant factor in poor performance.
- Currency issue, increased logistics and freight costs (due to disruptions in the Red Sea) and deferred
shipments impacted exports. - Raw material pricing remained stable throughout the quarter.
- Outlook for capsules business remains robust, optimistic about its continued growth.
- Outlook for the coming quarters is promising post resolution of logistic issues.
HPMC
- First HPMC line integration completed, and dry runs have successfully concluded.
- Poised to commence commercial production shortly.
- Plan to initiate the installation of the second and third HPMC line in due course of time.
API
- Same status as the last quarter.
- Still in the process of obtaining the final clearances from the Pollution Control Board and the license from the Drug Department.
- “A meeting scheduled for the coming week holds the promise of a favourable resolution.”
- Plan to commence the manufacturing of select intermediates, scaling up to APIs production after receiving the necessary licenses.
Disc. – Invested
Chirag’s Portfolio (10-02-2024)
@Cshar, Thanks for you response. Would it be a good choice to enter now in PSU banks as they have already run up a lot. I am looking for stocks to invest for long term.
After recent correction, SBI cards is at good valuation. Currently, borrowing cost is high, I would expect it to settle down in future and their margin will also improve. Also, spending is also improving which will also help increase credit card industry as whole.
AFFLE, Nazara and Tanla also look promising to me. What are your views on these stocks?